About PhyNexus
PhyNexus is a company based in San Jose (United States) founded in 2002 was acquired by Biotage in December 2018. PhyNexus offers products and services including Biotage® Initiator+, Biotage® Selekt, and ISOLUTE® SCX-2. PhyNexus operates in a competitive market with competitors including ArcherDX, RareCyte, Sequenta, seqWell and Paragon Genomics, among others.
- Headquarter San Jose, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biotage Ab
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PhyNexus
PhyNexus offers a comprehensive portfolio of products and services, including Biotage® Initiator+, Biotage® Selekt, and ISOLUTE® SCX-2.
Microwave synthesizer for efficient organic chemistry reactions
System for purification in drug discovery processes
Product for solid phase extraction in analytical workflows
Funding Insights of PhyNexus
Detailed funding history for PhyNexus
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in PhyNexus
PhyNexus has secured backing from 1 investor. Prominent investors backing the company include Biotage.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Organic synthesis, analytical, and peptide chemistry services for drug discovery and development
|
Locked | Locked | Locked |
Investor details for PhyNexus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PhyNexus
Investment portfolio details for PhyNexus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PhyNexus
Detailed financials for PhyNexus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phynexus Comparisons
Peer comparison for PhyNexus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PhyNexus
PhyNexus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, RareCyte, Sequenta, seqWell and Paragon Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| Locked | Locked | Locked |
NGS-based reagents and kits are supplied for life sciences research.
|
|
| Locked | Locked | Locked |
Provider of technologies and solutions genomic research and precision medicine
|
|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
Detailed competitors of PhyNexus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phynexus
Complete news archive for PhyNexus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhyNexus
PhyNexus was founded in 2002.
PhyNexus is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
PhyNexus was founded in 2002 in San Jose, United States, within the biotechnology sector. Automated liquid handlers and nucleic acid extractors are produced for molecular biology applications. Operations include plasmid DNA purification kits, affinity columns, specialty resins, gel filtration systems, normal phase columns, and ion exchange columns. Benchtop robotic instruments, such as the Auto plasmid MEA, and semi-automated protein extractors are also manufactured to support research workflows.
PhyNexus's top competitors include Neogen, Paragon Genomics and ArcherDX.
PhyNexus offers Biotage® Initiator+, Biotage® Selekt, and ISOLUTE® SCX-2.
PhyNexus has 1 investor. Key investors include Biotage.